Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non–muscle-invasive bladder cancer: Pro
M. Roumiguié, Peter C. Black
Topics & Concepts
MedicineGemcitabineDocetaxelBladder cancerOncologyUrologySecond-line therapyStandard of careInternal medicineCancerChemotherapyBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesEpigenetics and DNA Methylation